Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT02297672

Partial Breast Irradiation Using Interstitial Permanent Palladium-103 Seed Implant

Status
Active Not Recruiting
Phase
N/A
Study type
Interventional
Enrollment
75 (actual)
Sponsor
British Columbia Cancer Agency · Academic / Other
Sex
Female
Age
55 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Permanent Breast Seed Implant (PBSI) has been demonstrated to be a well accepted and well tolerated form of partial breast radiotherapy. This protocol aims to build on the initial experience and to further refine the technique and collect toxicity and cost data, especially in comparison to alternate forms of breast radiotherapy.

Detailed description

25 women with low stage (pT1pN0) breast cancer, grade 1 or 2, will be accrued for adjuvant partial breast radiotherapy using PBSI and prospectively followed for 5 years. The primary aims is to evaluate implant quality according to recognized dosimetric parameters. Secondary aims include elaboration of approaches to different technical scenarios imposed by variation in seroma size, shape and location within the breast (expanding the technical manual to include recommended approaches to implants in different sectors of the breast and in different size breasts), incorporation of the use of live 3D ultrasound in the procedure (as opposed to current use of 2D US), assessment of patient acceptance and quality of life, physician assessment of cosmesis, assessment of toxicity, and recording of cost to the patient and health care system compared to alternate forms of breast radiotherapy.

Conditions

Interventions

TypeNameDescription
RADIATIONStranded palladium seed interstitial implantInterstitial implantation of stranded palladium 103 seeds in seroma with a margin
DEVICE3 dimensional breast ultrasoundguidance of placement of interstitial needles in breast
DEVICEComputerized tomography (CT)Breast CT for planning and assessing interstitial implantation of radioactive seeds

Timeline

Start date
2015-02-01
Primary completion
2021-02-01
Completion
2026-02-01
First posted
2014-11-21
Last updated
2026-02-02

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT02297672. Inclusion in this directory is not an endorsement.